Jaguar Health, Inc. (JAGX) is a commercial stage pharmaceuticals company based in San Francisco, California, engaged in the development and commercialization of novel, plant-based, non-opioid, and sustainable prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhoea. It is publicly traded on Nasdaq under the symbol JAGX.
The company’s proprietary, patent-protected Mytesi® (crofelemer) product, the core ingredient of which comes from the latex of the South American tree known as Croton lechleri, is approved by the U.S FDA for treating noninfectious diarrhoea in adult patients with HIV/AIDS who are on anti-retroviral therapy. Crofelemer is a unique, first-in-class, ionic, molecular “normalizer” that works locally in the gut to regulate both the secretion and absorption of chloride and sodium ions and effectively treats chronic diarrhoea.
Beyond HIV, Jaguar Health is exploring other opportunities for Mytesi®, such as possible indications for cancer therapy-related diarrhoea, diarrhoea related to long-hauler COVID-19 syndrome, orphan-drug indications for short bowel syndrome (SBS), and congenital diarrheal disorders (CDD).
Jaguar Health's wholly-owned subsidiary in Italy, Naples BioSciences Srl, is focused on the discovery of sustainable plant-based compounds for potential indications of inflammatory, infectious, and GI diseases.
Jaguar Health, Inc. takes a keen interest in sustainability and environmental responsibility. The company works with local communities in the Amazon Rainforest to ensure ethical procurement of the raw latex used in its products, providing a sustainable economic activity that doesn't harm the forest. Meanwhile, the company runs animal health studies through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc.
Jaguar Health is led by a seasoned management team with a strong track record in gastrointestinal disorders and has collaborations with leading research institutions, making it a potent contender in the biopharmaceutical industry. The successful application of its proprietary technology to new indications could present significant growth opportunities for the company in the years to come.